Compare ENVX & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVX | SPTX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2020 | 2026 |
| Metric | ENVX | SPTX |
|---|---|---|
| Price | $5.13 | $20.62 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $13.61 | N/A |
| AVG Volume (30 Days) | ★ 5.3M | 179.3K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,821,000.00 | N/A |
| Revenue This Year | $30.37 | N/A |
| Revenue Next Year | $238.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.91 | N/A |
| 52 Week Low | $4.67 | $17.59 |
| 52 Week High | $16.49 | $22.98 |
| Indicator | ENVX | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.82 | 57.45 |
| Support Level | $4.75 | $17.89 |
| Resistance Level | $5.56 | $22.36 |
| Average True Range (ATR) | 0.38 | 1.98 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 18.52 | 49.36 |
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.